Oncternal Therapeutics Inc (ONCT)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

12230 EL CAMINO REAL SAN DIEGO, CA 92130

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.

Data as of 2021-07-25 16:16:36 -0400
Market Cap195.006 Million Shares Outstanding49.369 Million Avg 30-day Volume853.631 Thousand
P/E Ratio-10.57802 Dividend Yield0.0 EPS-0.641
Price/Sales58.35 Debt to Equity1.05 EBITDA-18.75 Million
Price to Book Value1.91 Forward PE-0.13 Enterprise Value95.643 Million
Total Cash111.211 Million Current Debt5.723 Million Gross Profit3.545 Million
BETA2.38457 52-week High/Low10.56 / 1.49 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from ONCT instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ONCT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ONCT BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

1.5 Thousand total shares from 1 transactions

Open Market Sells (S)

3.7 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

HALE DAVID F

  • Director
731,498 2021-06-30 2

LEAVITT CHASE C. GENERAL COUNSEL/SECRETARY

  • Officer
1,500 2021-06-11 2

CARTER MICHAEL G

  • Director
25,000 2021-05-25 2

WILLS ROBERT JAMES

  • Director
25,000 2021-05-25 1

MAZANET ROSEMARY

  • Director
25,000 2021-05-25 4

LARUE WILLIAM R

  • Director
25,000 2021-05-25 1

THEUER CHARLES

  • Director
25,000 2021-05-25 1

KISNER DANIEL L

  • Director
25,000 2021-05-25 1

NAKANISHI XIN

  • Director
25,000 2021-05-25 1

CHEN JINZHU PHD

  • Director
50,000 2021-05-25 2

KRISHNAN RAJESH CHIEF TECHNOLOGY OFFICER

  • Officer
0 2021-05-25 1

YAZJI SALIM CHIEF MEDICAL OFFICER

  • Officer
0 2021-05-25 1

BREITMEYER JAMES B CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
105,492 2021-03-18 3

VINCENT RICHARD G CHIEF FINANCIAL OFFICER

  • Officer
0 2021-02-11 1

KAUFMANN GUNNAR F. CHIEF SCIENTIFIC OFFICER

  • Officer
0 2021-02-11 1

BILINSKY IGOR CHIEF BUSINESS OFFICER

  • Officer
0 2021-02-11 1

AKER HAZEL M LEGAL COUNSEL

  • Officer
51,271 2020-07-21 0

SHANGHAI PHARMACEUTICAL (USA) INC.

SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.

  • 10% Owner
3,544,431 2020-07-21 0

SHANGHAI PHARMACEUTICALS (HK) INVESTMENT LTD

  • 10% Owner
1,049,317 2020-07-21 0

CHO MAN

  • Director
0 2020-06-11 0

HSU FRANK J. CHIEF MEDICAL OFFICER

  • Officer
0 2020-03-17 0

LIU YANJUN

  • Director
0 2019-09-12 0

SHANGHAI PHARMACEUTICAL (USA) INC.

  • 10% Owner
0 2019-06-07 0

HYDE JOSEPH R III

  • Director
  • 10% Owner
6,877,615 2019-01-02 0

NEIL GARRY ARTHUR

  • Director
36,759 2019-01-02 0

ROBINSON KENNETH S

  • Director
44,105 2018-10-01 0

YOUNG DIANE C. VP, CHIEF MEDICAL OFFICER

  • Officer
45,936 2018-07-13 0

DOGGRELL HENRY PATTON VP, CHIEF LEGAL OFFICER

  • Officer
48,175 2018-06-20 0

SHACKELFORD JASON T PRIN FIN. & ACCT. OFFICER

  • Officer
19,548 2018-06-20 0

GLASS J KENNETH

  • Director
0 2018-05-10 0

HANOVER MARC STEVEN CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
172,049 2018-01-05 0

PYRAMID PEAK FOUNDATION

  • 10% Owner
4,390,243 2017-09-29 0

FURR BARRY J. A.

  • Director
48,469 2015-01-02 0

DALTON JAMES T VP, CHIEF SCIENTIFIC OFFICER

  • Officer
0 2014-06-06 0

SCHULER JACK W

  • 10% Owner
6,165,261 2014-03-19 0

STEINER MITCHELL SHUSTER CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
4,673,367 2014-01-29 0

MOSTELLER MARK EDWARD VICE PRESIDENT, CFO

  • Officer
7,282 2013-07-08 0

SEAR TIMOTHY R G

  • Director
195,668 2013-01-01 0

MORTON RONALD A JR VP, CHIEF MEDICAL OFFICER

  • Officer
0 2012-01-01 0

PONTIUS JOHN HOFMANN

  • Director
157,339 2011-07-01 0

DEENER GREGORY A VICE PRESIDENT

  • Officer
0 2011-01-01 0

KARR ROBERT W

  • Director
0 2010-04-30 0

HESSELBERG JEFFREY G VICE PRESIDENT, REGULATORY

  • Officer
No longer subject to file 2008-07-30 0

BARNETTE K GARY VICE PRESIDENT

  • Officer
No longer subject to file 2008-07-30 0

WEST CHRISTOPHER K VICE PRESIDENT - SALES

  • Officer
No longer subject to file 2008-07-30 0

BROWN MICHAEL DENNY VICE PRESIDENT

  • Officer
No longer subject to file 2008-07-30 0

DODSON SHONTELLE VICE PRESIDENT

  • Officer
No longer subject to file 2008-07-30 0

RODRIGUEZ DOMINGO VICE PRESIDENT

  • Officer
No longer subject to file 2008-07-30 0

CLARKSON ANDREW M

  • Director
No longer subject to file 2008-06-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

HALE DAVID F - Director by hale biopharma ventures, llc

2021-07-02 17:01:16 -0400 2021-06-30 S 3,669 $4.75 d 713,152 indirect -2.6549 -6.4159 0.0 1 -6.4159 6

LEAVITT CHASE C. - Officer GENERAL COUNSEL/SECRETARY

2021-06-15 18:00:30 -0400 2021-06-11 P 1,500 $5.45 a 1,500 direct -2.0446 -3.3457 0.9294 4 -3.5316 5

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 18:15:03 UTC -0.4045 0.4845 2200000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 17:45:03 UTC -0.4045 0.4845 2200000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 17:15:03 UTC -0.4045 0.4845 2200000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 16:45:03 UTC -0.4264 0.5064 2200000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 16:15:02 UTC -0.4264 0.5064 2200000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 15:45:03 UTC -0.4264 0.5064 2200000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 15:15:03 UTC -0.4264 0.5064 2200000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 14:45:02 UTC -0.3951 0.4751 2200000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 14:15:03 UTC -0.3951 0.4751 2100000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 13:45:02 UTC -0.3951 0.4751 2100000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 13:15:03 UTC -0.3951 0.4751 2100000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-28 12:45:03 UTC -0.3951 0.4751 2100000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-27 22:15:03 UTC -0.3951 0.4751 2000000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-27 21:45:03 UTC -0.3951 0.4751 2000000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-27 21:15:03 UTC -0.3951 0.4751 2000000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-27 20:45:03 UTC -0.3986 0.4786 2000000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-27 20:15:03 UTC -0.3986 0.4786 2000000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-27 19:45:02 UTC -0.3986 0.4786 2000000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-27 19:15:02 UTC -0.3986 0.4786 2000000
ONCTERNAL THERAPEUTICS INC ONCT 2021-07-27 18:45:03 UTC -0.4318 0.5118 2000000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments